Viking Therapeutics Inc

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  7563.1

• Ticker

  VKTX.O

• ISIN

  US92686J1060

• IPO date

  2015-04-29

• Availability on Russian exchanges

  No

• Reporting for

  2024-02-07

• Date fact. publication of reports

  2023-12-31

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel therapies for metabolic and endocrine disorders. The Company's lead clinical program includes VK2809, which is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. The Company is conducting VOYAGE study, a Phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NAS). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TR? for X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. Its Other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).